LB Pharmaceuticals Announces Presentation at the 43rd Annual J.P. Mogan Healthcare Conference

NEW YORK, Jan. 06, 2025 (GLOBE NEWSWIRE) — LB Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia, today announced that Heather Turner, Chief Executive Officer, will present at the 43^rd Annual J.P. Morgan Healthcare conference in San Francisco on Monday, January 13, 2025 at 1:30 p.m. PT.

About LB-102
LB-102 is a once-daily, orally administered, small molecule being developed as a potential first-in-class benzamide antipsychotic in the U.S. Designed to deliver improved efficacy, safety, and tolerability, LB-102 targets both positive symptoms and negative symptoms of schizophrenia, potentially offering a comprehensive approach to disease management. LB-102 has been studied in NOVA¹, a robust registrational quality Phase 2 trial in both size and statistical analysis plan, in which LB-102’s potential efficacy, safety and tolerability is being evaluated.

About LB Pharmaceuticals
LB Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia. The company’s lead candidate, LB-102, is a potential first-in-class benzamide antipsychotic in the U.S. designed to address critical gaps in the current standard of care by providing comprehensive disease management with a generally safe and tolerable profile. LB Pharmaceuticals is backed by institutional investors Deep Track Capital, TCGx Crossover, Vida Ventures, and Pontifax. To learn more, visit our website at https://lbpharma.us/.

Media Contact:
Kristin Politi, Ph.D.
LifeSci Communications
kpoliti@lifescicomms.com